The Louisiana Senate Health and Welfare Committee has approved a pioneering bill that would establish a state-led psychedelic-assisted therapy pilot program. Sponsored by Senator Patrick McMath (R), Senate Bill 43 proposes utilizing opioid settlement funds to finance clinical trials for substances with high therapeutic potential, including psilocybin and ibogaine. The legislation marks a significant shift in state policy, directly fueled by the advocacy of military veterans and the urgent need for novel treatments for opioid use disorder and treatment-resistant mental health conditions.
Under the proposed framework, the Louisiana Department of Health (LDH) would oversee the facilitation of these trials, ensuring that all research remains strictly within the bounds of federal law. Any study conducted under the pilot program must navigate the formal FDA investigational drug approval process and secure necessary permitting from the DEA. This emphasis on federal compliance and rigorous physical and mental health screenings for participants underscores the state’s commitment to establishing a safe, evidence-based, and medicalized pathway for psychedelic care.
A unique feature of SB 43 is its economic and collaborative structure, particularly regarding ibogaine research. The bill authorizes Louisiana to participate in a national consortium for ibogaine drug development, encouraging academic institutions to collaborate across state lines to bolster the prospects of FDA approval. Furthermore, the legislation includes a revenue-sharing provision: should a prescription drug be successfully developed and approved as a result of these state-funded trials, 20 percent of the resulting profits would be returned to the state treasury.
Senator McMath, who previously chaired a task force on the therapeutic benefits of psychedelics, framed the bill as an opportunity for Louisiana to lead the nation in innovative medicine. By leveraging settlement dollars intended to remediate the damage of the opioid epidemic, the state aims to transform a history of crisis into a future of clinical breakthrough. As the bill moves forward, it sets a professional precedent for how states can responsibly operationalize the research and eventual delivery of prescription psychedelic therapies.
Source: Marijuana Moment
